Journal for ImmunoTherapy of Cancer · 2020 · 31 citations · 28 references
Life SciencesHematologyImmunologyCell TherapyImmunoregulationImmunotherapyCancer ImmunotherapyCell-based ImmunotherapyChimeric Antigen Receptor T-cell TherapyCytotoxic T Lymphocyte ResponsesT Cell ActivationT Cell BiologyB-cell Acute Lymphoblastic LeukemiaB-cell Malignancy Cellular TherapyHematologic Malignancy Car T-cell TherapyImmunosuppressive ConditioningImmunosuppressive FunctionImmunosuppressive MicroenvironmentT Cell Response InductionT Cell-based Immunotherapy
BACKGROUND: Although adoptive transfer of CD19-directed chimeric antigen receptor (CAR) T-cells (CD19-CAR T-cells) achieves high rates of complete response in patients with B-cell acute lymphoblastic leukemia (B-ALL), relapse is common. Bone marrow (BM) mesenchymal stem/stromal cells (BM-MSC) are key components of the hematopoietic niche and are implicated in B-ALL pathogenesis and therapy resistance. MSC exert an immunosuppressive effect on T-cells; however, their impact on CD19-CAR T-cell activity is understudied. METHODS: We performed a detailed characterization of BM-MSC from pediatric patients with B-ALL (B-ALL BM-MSC), evaluated their immunomodulatory properties and their impact on CD19-CAR T-cell activity in vitro using microscopy, qRT-PCR, ELISA, flow cytometry analysis and in vivo using a preclinical model of severe colitis and a B-ALL xenograft model. RESULTS: While B-ALL BM-MSC were less proliferative than those from age-matched healthy donors (HD), the morphology, immunophenotype, differentiation potential and chemoprotection was very similar. Likewise, both BM-MSC populations were equally immunosuppressive in vitro and anti-inflammatory in an in vivo model of severe colitis. Interestingly, BM-MSC failed to impair CD19-CAR T-cell cytotoxicity or cytokine production in vitro using B-ALL cell lines and primary B-ALL cells. Finally, the growth of NALM6 cells was controlled in vivo by CD19-CAR T-cells irrespective of the absence/presence of BM-MSC. CONCLUSIONS: Collectively, our data demonstrate that pediatric B-ALL and HD BM-MSC equally immunosuppress T-cell responses but do not compromise CD19-CAR T-cell activity.
28
Sowmya Viswanathan, Yufang Shi, Jacques Galipeau et al. · Cytotherapy · 2019 · 829 citations
Richard Burt, Aditi Dey, Sarah Aref et al. · Blood · 2019 · 243 citations · Full text